Attached files
Exhibit
32.1
CERTIFICATE
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of Tetragenex Pharmaceuticals, Inc. (the
“Company”) on Form 10-Q for the period ending March 31, 2010 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), Martin
Schacker, as Co-Chief Executive Officer and Principal Financial Officer hereby
certify, pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:
|
|
1.
|
The
report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934;
and
|
|
|
2.
|
The
information contained in the report fairly presents, in all material
respects, the financial condition and results of operations of the Company
as of and for the period covered by the
Report.
|
|
/s/ Martin
Schacker
|
|
| Martin Schacker | |
| Co-Chief Executive Officer and Principal Financial Officer | |
|
May
13, 2010
|